The Food and Drug Administration has approved Gardasil, the first vaccine developed to prevent cervical cancer and precancerous genital lesions and genital warts due to certain types of human papillomavirus (HPV). The vaccine is approved for use in females ages 9 years to 26 years. Gardasil was evaluated and approved in six months under the FDA's priority review process--a process for products with potential to provide significant health benefits.
美国食品药品监督管理局已批准加德西疫苗，这是首款研发用于预防由某些类型的人乳头瘤病毒（HPV）引起的宫颈癌、癌前生殖器病变和尖锐湿疣的疫苗。该疫苗被批准用于9岁至26岁的女性。加德西疫苗在美国食品药品监督管理局的优先审评程序下，历时六个月进行评估并获批，优先审评程序是针对有潜力带来重大健康益处的产品的审评程序。
